Oncolytics Nears Full Site Activation in Colorectal Cancer Trial, Eyes Year-End Interim Data
ONCY is trading near its 52-week low of $0.642 (6.4% above the low).
Summary
Oncolytics has activated nearly all planned clinical sites for Part A of its REO 033 colorectal cancer study, with multiple patients now enrolled. The company expects to report interim data by year-end 2026, based on patients enrolled by end of October. This follows the July announcement of rapid site activation and the August FDA alignment on a potential pivotal Part B expansion. The FDA alignment provides a potential path to accelerated approval based on objective response rate and full approval based on progression-free survival. The update signals operational momentum and a near-term data catalyst, though the company remains in a going-concern situation with limited cash. The interim readout will be critical for validating the promising REO 022 efficacy signals in a randomized setting.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — FDA alignment provides potential path to accelerated approval based on objective response rate and full approval based on progression-free survival.
At the time of this announcement, ONCY was trading at $0.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $87.1M. The 52-week trading range was $0.64 to $1.51. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.